Immix Biopharma is trading 5.6% lower at $9.56, with no confirmed company-specific announcement explaining the decline. - Recent coverage discussed earlier clinical-trial data and a stock offering, but neither is established as the cause of this session’s drop. - The broader market is higher, while biotechnology is down 2.5%; sector weakness may be relevant but does not conclusively explain the move. No trading-volume figure was provided.